NM_000742.4:c.1052A>G
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PP3_ModerateBS2
The NM_000742.4(CHRNA2):c.1052A>G(p.Asn351Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000155 in 1,613,952 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000742.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 151998Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 250948Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135658
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461836Hom.: 0 Cov.: 32 AF XY: 0.0000124 AC XY: 9AN XY: 727210
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152116Hom.: 0 Cov.: 33 AF XY: 0.0000672 AC XY: 5AN XY: 74362
ClinVar
Submissions by phenotype
Autosomal dominant nocturnal frontal lobe epilepsy Uncertain:1
This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 351 of the CHRNA2 protein (p.Asn351Ser). This variant is present in population databases (rs770305730, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with CHRNA2-related conditions. This missense change has been observed in at least one individual who was not affected with CHRNA2-related conditions (internal data). ClinVar contains an entry for this variant (Variation ID: 575518). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt CHRNA2 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Inborn genetic diseases Uncertain:1
The c.1052A>G (p.N351S) alteration is located in exon 6 (coding exon 5) of the CHRNA2 gene. This alteration results from a A to G substitution at nucleotide position 1052, causing the asparagine (N) at amino acid position 351 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
not provided Uncertain:1
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Autosomal dominant nocturnal frontal lobe epilepsy 4 Uncertain:1
The inherited missense variant c.1052A>G, p.Asn351Ser in the CHRNA2 gene has not been reported in the available literature.The variant has a 0.003% allele frequency in the gnomAD database (5 out of 151,998 heterozygous alleles), suggesting it is not a common benign variant in the populations represented in this database. In silico analysis support a deleterious effect on the gene or gene product. The variant resides at the Neurotransmitter-gated ion-channel transmembrane region domain. Based on the available evidence, the c.1052A>G, p.Asn351Ser missense variant in the CHRNA2 gene is classified as a variant of uncertain significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at